Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 65


[Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)].

Wang M, Han HH, Guo R, Liu YF, Jiang ZX, Sun H.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Oct;25(5):1482-1486. doi: 10.7534/j.issn.1009-2137.2017.05.035. Chinese.


[The efficacy and safety of the patients of myelodysplastic syndromes-refractory anemia with excess blasts treated with decitabine alone or CAG/HAG regimen].

Xu ZF, Qin TJ, Zhang HL, Fang LW, Zhang Y, Pan LJ, Hu NB, Qu SQ, Li B, Xiao ZJ.

Zhonghua Xue Ye Xue Za Zhi. 2017 Jul 14;38(7):572-577. doi: 10.3760/cma.j.issn.0253-2727.2017.07.004. Chinese.


Acquired elliptocytosis in the setting of a refractory anemia with excess blasts and del(20q).

Boutault R, Eveillard M.

Blood. 2016 May 26;127(21):2646. doi: 10.1182/blood-2016-03-703876. Epub 2016 May 26. No abstract available.


Pseudo-Chédiak-Higashi granules and other unusual cytoplasmic inclusions in refractory anaemia with excess blasts-2.

La Gioia A, Bombara M, Fiorini F, Fiorini M.

Br J Haematol. 2017 Jan;176(2):156. doi: 10.1111/bjh.14405. Epub 2016 Nov 4. No abstract available.


[Analysis of the impact of decitabine treatment cycles on efficacy and safety in patients of myelodysplastic syndrome-refractory anemia with excess blasts].

Luo XP, Xu ZF, Qin TJ, Zhang Y, Zhang HL, Fang LW, Pan LJ, Hu NB, Qu SQ, Li B, Xiao ZJ.

Zhonghua Xue Ye Xue Za Zhi. 2016 Oct 14;37(10):870-875. doi: 10.3760/cma.j.issn.0253-2727.2016.10.011. Chinese.


Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States.

Zeidan AM, Wang R, Gross CP, Gore SD, Huntington SF, Prebet T, Abel GA, Davidoff AJ, Ma X.

Leuk Lymphoma. 2017 Apr;58(4):982-985. doi: 10.1080/10428194.2016.1214954. Epub 2016 Aug 25. No abstract available.


Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts.

Wang SA, Patel KP, Pozdnyakova O, Peng J, Zuo Z, Dal Cin P, Steensma DP, Hasserjian RP.

Mod Pathol. 2016 Oct;29(10):1221-31. doi: 10.1038/modpathol.2016.118. Epub 2016 Jul 15.


Low Dose Cytosine Arabinoside and Azacitidine Combination in Elderly Patients with Acute Myeloid Leukemia and Refractory Anemia with Excess Blasts (MDS-RAEB2).

Atalay F, Ateşoğlu EB.

Indian J Hematol Blood Transfus. 2016 Mar;32(1):46-53. doi: 10.1007/s12288-015-0509-2. Epub 2015 Feb 1.


Myeloid Sarcoma of the Bladder in the Setting of Refractory Anemia with Excess Blasts-2 (RAEB-2).

Grantham JT, Howell DM, Bacaj PJ, Coad JE, Vos JA.

W V Med J. 2015 Nov-Dec;111(6):34-6.


Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG).

Becker H, Suciu S, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Muus P, Pflüger KH, Hagemeijer A, Schaefer HE, Fiaccadori V, Baron F, Ganser A, Aul C, de Witte T, Wijermans PW, Lübbert M.

Ann Hematol. 2015 Dec;94(12):2003-13. doi: 10.1007/s00277-015-2489-6. Epub 2015 Sep 24.


Isolated trisomy 13 in refractory anemia with excess blasts: report of two cases and a brief literature review of this possible association.

Mu Q, Chen Y, Zhu H, Zhang Y, Wu N, Lou Y, Shi S, Wu Y, Shi C, Ouyang G.

Leuk Lymphoma. 2016 Feb;57(2):493-495. doi: 10.3109/10428194.2015.1067698. Epub 2015 Aug 28. No abstract available.


Systemic mastocytosis emerging after azacitidine treatment of refractory anaemia with excess blasts type 2.

Xu Z, Shier L, Sabloff M, McCurdy A, Sheppard D, Bredeson C.

Br J Haematol. 2014 Oct;167(2):147. doi: 10.1111/bjh.13024. Epub 2014 Jul 9. No abstract available.


Proteome changes in the plasma of myelodysplastic syndrome patients with refractory anemia with excess blasts subtype 2.

Majek P, Riedelova-Reicheltova Z, Suttnar J, Pecankova K, Cermak J, Dyr JE.

Dis Markers. 2014;2014:178709. doi: 10.1155/2014/178709. Epub 2014 May 25.


[A case in which chromosome 5q deletion syndrome resistant to lenalidomide therapy transformed to refractory anemia with excess blasts].

Yamada M, Kuroda H, Jomen W, Yoshida M, Miura S, Abe T, Sakurai T, Fujii S, Maeda M, Fujita M, Nagashima K, Arihara Y, Hirako T, Kato J.

Gan To Kagaku Ryoho. 2013 Dec;40(13):2593-7. Japanese.


[Transfusional independence in a patient with refractory anemia with excess blasts-2 refractory to 5-azacitidine treated with deferasirox and colony stimulating factors].

Moreno de Gusmão B, Guinea de Castro JM, Perez-Persona E, Oiartzabal I.

Med Clin (Barc). 2014 Jan 21;142(2):91-2. doi: 10.1016/j.medcli.2013.04.023. Epub 2013 Jun 20. Spanish. No abstract available.


Pathogenetic role of ETV6 fusion gene in leukemic transformation of myelodysplastic syndrome refractory anemia with excess blasts-1 with a new, rare translocation t(11;19)(q24.3;q13.12) and insertion ins(6;12)(p22.3p13).

Jarošová M, Rohoň P, Živná J, Peková S, Nedomová R, Holzerová M, Mičková P, Reptová S, Papajík T, Indrák K.

Leuk Lymphoma. 2014 Apr;55(4):950-3. doi: 10.3109/10428194.2013.814127. Epub 2013 Jul 29. No abstract available.


A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2.

Holkova B, Supko JG, Ames MM, Reid JM, Shapiro GI, Perkins EB, Ramakrishnan V, Tombes MB, Honeycutt C, McGovern RM, Kmieciak M, Shrader E, Wellons MD, Sankala H, Doyle A, Wright J, Roberts JD, Grant S.

Clin Cancer Res. 2013 Apr 1;19(7):1873-83. doi: 10.1158/1078-0432.CCR-12-2926. Epub 2013 Mar 20.


Huge multinucleated megaloblasts found in a patient with refractory anemia with excess blasts-1.

Ohgiya D, Matsushita H, Kojima M, Ando K.

Int J Hematol. 2012 Nov;96(5):531-2. doi: 10.1007/s12185-012-1212-9. Epub 2012 Oct 26. No abstract available.


[Effective treatment of myelodysplastic syndromes-refractory anemia with excess blasts type II by decitabine: a case report].

Bao L, Huang XJ.

Zhonghua Xue Ye Xue Za Zhi. 2012 Jul;33(7):573. Chinese. No abstract available.


Plasma protein alterations in the refractory anemia with excess blasts subtype 1 subgroup of myelodysplastic syndrome.

Májek P, Reicheltová Z, Suttnar J, Cermák J, Dyr JE.

Proteome Sci. 2012 May 8;10(1):31. doi: 10.1186/1477-5956-10-31.

Supplemental Content

Loading ...
Support Center